BPC 157 (acetate) (Synonyms: GEPPPGKPADDAGLV, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) |
| カタログ番号GC46946 |
多様な生物学的活性を持つペンタデカペプチド
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1628202-19-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Body protection compound 157 (BPC 157) is a pentadecapeptide fragment of BPC that has been found in gastric juice and has diverse biological activities.1 It increases cell migration of, and F-actin formation in, primary rat tendon fibroblasts when used at a concentration of 2 µg/ml.2 BPC 157 (0.01 and 10 µg/kg, i.p.) reduces paw swelling, bone erosion, and inflamed joint mononuclear cell infiltration in a rat model of rheumatoid arthritis induced by complete Freund's adjuvant (CFA).3 It decreases the lesion size of gastric ulcers induced by indomethacin , aspirin , or diclofenac in rats at the same doses. BCP 157 (0.01 and 10 µg/kg, i.p.) decreases the duration of catalepsy and reduces tremor severity in a mouse model of Parkinson's disease induced by MPTP.4
1.Sikiric, P., Seiwerth, S., Rucman, R., et al.Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implicationsCurr. Neuropharmacol.14(8)857-865(2016) 2.Chang, C.-H., Tsai, W.-C., Lin, M.-S., et al.The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migrationJ. Appl. Physiol.110(3)774-780(2011) 3.Sikiric, P., Seiwerth, S., Grabarevic, Z., et al.Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in ratsJ. Physiol. (Paris)91(3-5)113-122(1997) 4.Sikiric, P., Marovic, A., Matoz, W., et al.A behavioural study of the effect of pentadecapeptide BPC 157 in Parkinson's disease models in mice and gastric lesions induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineJ. Physiol. (Paris)93(6)505-512(1999)
| Cas No. | 1628202-19-6 | SDF | |
| 同義語 | GEPPPGKPADDAGLV, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | ||
| Canonical SMILES | C[C@@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)=O)=O)=O)NC([C@@H]1CCCN1C([C@@H](NC(CNC([C@H]2N(C([C@@H]3CCCN3C([C@@H]4CCCN4C([C@@H](NC(CN)=O)CCC(O)=O)=O)=O)=O)CCC2)=O)=O)CCCCN)=O)=O.CC(O)=OC[C@@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)=O)=O)=O)NC([C@@H]1CCCN1C([C@@H](NC(CNC([C@H]2N(C([C@@H]3CCCN3C([C@@H]4CCCN4C([C@@H](NC(CN)=O)CCC(O)=O)=O)=O)=O)CCC2)=O)=O)CCCCN)=O)=O.CC(O)=O | ||
| Formula | C62H98N16O22.XC2H4O2 | M.Wt | 1419.5 |
| 溶解度 | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.7045 mL | 3.5224 mL | 7.0447 mL |
| 5 mM | 0.1409 mL | 0.7045 mL | 1.4089 mL |
| 10 mM | 0.0704 mL | 0.3522 mL | 0.7045 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *